Nxera Pharma Co., Ltd. is excited to announce that they will be hosting an R&D Day on 6 November 2024 at 16:30 JST. The event will take place virtually through a Zoom webinar. To participate, kindly pre-register for the event by clicking on the provided link.
During the R&D Day, attendees will have the opportunity to hear from key presenters within the company. The lineup includes Chris Cargill, the President and CEO of Nxera Pharma, Dr. Matt Barnes, Executive Officer and President of Nxera Pharma UK, Dr. Makoto Sugita, Executive Officer and Chief Medical Officer (CMO) of Nxera Pharma Japan, and Hironoshin Nomura, Executive Officer and CFO.
Presentation slides will be available for viewing by 16:00 JST on 6 November through the investor section of the company’s website.
Nxera Pharma, formerly known as Sosei Heptares, is a biopharmaceutical company focused on developing specialty medicines to address the unmet needs of patients in Japan and globally. The company has a robust pipeline of over 30 active programs in various stages of development, both internally and through collaborations with other industry leaders. Their research targets key areas such as neurology, GI and immunology, metabolic disorders, and rare diseases, utilizing their innovative GPCR-targeted structure-based drug discovery NxWaveTM platform.
With over 350 employees located in key cities around the world, including Tokyo, Osaka, London, Cambridge, Basel, and Seoul, Nxera Pharma is committed to driving innovation in the pharmaceutical industry. The company is listed on the Tokyo Stock Exchange under the ticker symbol 4565.
For more information about Nxera Pharma and their research initiatives, visit their website or connect with them on LinkedIn, Twitter, and YouTube.
For media and investor inquiries, please reach out to the designated contacts at Nxera Pharma or MEDiSTRAVA for international media coverage.
As with any forward-looking statements, there are inherent risks and uncertainties that could impact Nxera Pharma’s actual results. Factors such as clinical trial outcomes, patent protections, regulatory approvals, and competition in the market can all influence the company’s success. Prospective investors are advised to exercise caution when considering these forward-looking statements and to seek updated information as the situation evolves.
